The week of August 31 was broadly constructive on upgrades, but the tone soured fast in pockets of utilities and biotech. Bank of America's twin downgrades of PCG and EIX dominated the utility tape, while a wave of analyst cuts battered rare-disease specialist RARE. Net across the week, upgrades outnumbered downgrades, with financials and tech drawing the most bullish reassessments.
Financials led the upgrade cycle. Morgan Stanley's Mike Cyprys raised HOOD to Overweight with a $150 target. That implies 43% upside from $104.81. Raymond James reinstated ALLY at Strong Buy with a $55 target, implying 31% upside. Piper Sandler lifted SFNC to Overweight, raising the target to $27.50.
Deutsche Bank initiated a broad tech sweep. The firm started ANET at Buy with a $220 target and CSCO at Buy with a $135 target. Both follow strong recent earnings momentum. Macquarie upgraded AVGO to Outperform with a $490 target — 33% above the $367 close.
Evercore ISI turned bullish on two names. The firm upgraded DUOL to Outperform and doubled its target to $210. It also upgraded DE to Outperform at $813 and CNH to Outperform at $18, lifting its prior target by 44%.
Piper Sandler upgraded AKAM to Overweight but cut the target 11% to $125, flagging GPU delays as a near-term drag. The firm also lifted TEM to Overweight with a $76 target, up 36% from the prior call.
Other notable upgrades:
Utilities took the hardest hit. Bank of America slashed PCG to Neutral from Buy, cutting the target 46% to $13 from $24. The stock fell 20% on the day. Short interest jumped 14.9% in a single session. Truist followed with its own downgrade of PCG, cutting the target to $17. Four analysts cut ratings on the name in the week. BofA also downgraded EIX to Neutral, cutting the target 37% to $51.
Biotech saw a coordinated pullback on RARE. Baird, Evercore ISI, JP Morgan, and William Blair all moved to neutral or lower. JP Morgan cut its target 55%. Baird analyst Joel Beatty cut 60% to $16. Consensus remains Buy at $41, but the gap between street consensus and the new targets is wide and closing.
Other notable downgrades:
Deutsche Bank initiated coverage across several tech names. INGM received a Hold at $30. ATEN got a Hold at $28. Both carry implied modest downsides from current levels.
Utilities: Coordinated bear turn. BofA's double downgrade of PCG and EIX — with target cuts of 46% and 37% respectively — signals a firm-wide reassessment of California utility risk. Truist's follow-on PCG cut reinforces the move. The sector's fundamentals face regulatory and wildfire liability scrutiny.
Tech: Selective conviction. Deutsche Bank's initiation sweep across networking and infrastructure names (ANET, CSCO) reflects post-earnings confidence. Macquarie's AVGO upgrade adds to a pattern of large-cap semiconductor upgrades. Piper Sandler's AKAM move is bullish on structure but cautious on near-term execution — a common hedge this week.
Biotech/Rare Disease: Rating reset. RARE drew four separate downgrades in two days. The coordinated move suggests pipeline data disappointed broadly. ALMS also attracted mixed signals — one upgrade, one downgrade — on the same stock, reflecting deep uncertainty around TYK2 inhibitor positioning.
Financials: Broad optimism. HOOD, ALLY, IBKR, and SFNC all attracted constructive moves. The theme is improving retail brokerage volumes and rate-driven net interest income. Short interest on HOOD fell 14% over the month — bears are retreating alongside analyst upgrades.
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
